Praluent and Diphenhydramine Interaction: What Patients and Clinicians Need to Know

How Alirocumab Is Metabolized, and Why It Matters for Drug Interactions

Alirocumab does not interact with diphenhydramine at the pharmacokinetic level. Understanding why requires a brief look at how monoclonal antibodies are cleared from the body, because the mechanism is fundamentally different from small-molecule drugs.

Alirocumab is a fully human IgG1 monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), preventing PCSK9 from degrading LDL receptors on hepatocytes. Once alirocumab binds PCSK9, the complex is internalized and degraded into small peptides and amino acids through lysosomal proteolysis. This is the same process used to recycle any other protein the body no longer needs.

No CYP Enzyme Involvement

Because alirocumab is a large-molecule biologic, it is not a substrate, inhibitor, or inducer of any cytochrome P450 enzyme, including CYP2D6, which metabolizes diphenhydramine. The FDA-approved Praluent prescribing information states explicitly that no formal drug-drug interaction studies were conducted, because the biological basis for pharmacokinetic interactions does not exist for monoclonal antibodies cleared by proteolysis [1].

Diphenhydramine, by contrast, is a small molecule. It is primarily metabolized by CYP2D6 and, to a lesser degree, CYP3A4, with a half-life of approximately 4 to 8 hours in healthy adults [2]. Its CYP2D6 pathway is irrelevant to alirocumab.

No P-glycoprotein or Transporter Effects

Neither alirocumab nor diphenhydramine's effect on P-glycoprotein (P-gp) or organic anion-transporting polypeptides (OATPs) is clinically significant in the context of their co-administration. Diphenhydramine has some P-gp substrate characteristics that affect its CNS penetration, but alirocumab has no interaction with P-gp whatsoever, given its size and route of elimination [1].

The practical conclusion: a patient taking 75 mg or 150 mg of alirocumab subcutaneously every two weeks will have exactly the same alirocumab plasma exposure regardless of whether they also take diphenhydramine 25 mg or 50 mg by mouth.

The Real Risk: Pharmacodynamic Concerns in Cardiovascular Patients

The absence of a pharmacokinetic interaction does not mean the combination is automatically low-risk for every patient. Praluent is indicated for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous FH (HoFH), or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statins [1]. These patients often carry a significant burden of comorbid conditions and polypharmacy. Diphenhydramine's pharmacodynamic profile creates several concerns in this population.

Anticholinergic Cardiovascular Effects

Diphenhydramine blocks muscarinic acetylcholine receptors. At therapeutic doses (25 to 50 mg), this produces sinus tachycardia, heart rate increases of 10 to 25 beats per minute have been measured in controlled studies [3]. For a patient with ASCVD, a resting tachycardia raises myocardial oxygen demand. One epidemiological study published in JAMA Internal Medicine found that higher cumulative anticholinergic drug burden was associated with increased cardiovascular event risk in older adults [4]. Diphenhydramine carries one of the highest anticholinergic burden scores (score of 3 on the Anticholinergic Cognitive Burden scale) [5].

CNS Depression and Fall Risk

Diphenhydramine's first-generation antihistamine chemistry allows substantial blood-brain barrier penetration. Sedation is the most commonly reported adverse effect, affecting an estimated 25 to 50% of users. In adults over 65 with established cardiovascular disease, a population that may already be on beta-blockers, calcium-channel blockers, or nitrates, the additive CNS depression from diphenhydramine raises fall risk meaningfully. The American Geriatrics Society Beers Criteria explicitly lists diphenhydramine as a drug to avoid in older adults, citing sedation, confusion, dry mouth, constipation, and urinary retention [6].

QT-Interval Considerations

Diphenhydramine has a documented, dose-dependent QT-prolonging effect. A 2019 analysis in the Journal of Clinical Pharmacology identified diphenhydramine as a drug with conditional QT-prolonging risk, particularly at doses above 50 mg or in patients with baseline QT prolongation [7]. Alirocumab itself has no reported QT effects [1]. However, many patients on Praluent are also taking statins, and certain statins (notably rosuvastatin at high doses) have been associated with modest QT changes. The combination of diphenhydramine with a substrate-heavy cardiac medication regimen deserves a baseline ECG assessment in high-risk individuals.

Praluent Drug Interactions: The Broader Picture

Diphenhydramine is not alone in being pharmacodynamically relevant to Praluent patients. Because alirocumab has no pharmacokinetic interactions, essentially every drug-interaction concern involving Praluent is pharmacodynamic or disease-state-mediated.

Statins and Alirocumab

Alirocumab is almost always co-prescribed with a maximally tolerated statin. The ODYSSEY OUTCOMES trial (N=18,924) randomized patients with a recent acute coronary syndrome to alirocumab 75 mg to 150 mg every two weeks versus placebo on top of high-intensity statin therapy. The trial showed a 15% relative risk reduction in major adverse cardiovascular events (MACE) at a median follow-up of 2.8 years (hazard ratio 0.85, 95% CI 0.78 to 0.93, P<0.001) [8]. No clinically meaningful pharmacokinetic interactions between alirocumab and atorvastatin, rosuvastatin, or simvastatin were identified in the Praluent FDA label [1].

Ezetimibe and Alirocumab

Ezetimibe is frequently added to maximize LDL-C lowering. No pharmacokinetic interaction exists between ezetimibe and alirocumab. Both are safe to co-administer per current ACC/AHA guidelines on the management of blood cholesterol, which recommend adding a PCSK9 inhibitor when LDL-C remains above 70 mg/dL on maximally tolerated statin plus ezetimibe in very-high-risk ASCVD patients [9].

Warfarin and Anticoagulants

Some Praluent patients require anticoagulation. Alirocumab does not alter warfarin pharmacokinetics (no CYP2C9 or CYP3A4 involvement). INR monitoring should follow standard warfarin protocols and is not intensified specifically because of alirocumab.

Immunosuppressants

For patients on immunosuppressive monoclonal antibodies or biologics, no formal interaction data exist for alirocumab. The theoretical concern is that immunosuppression might alter the formation or clearance of anti-alirocumab antibodies. The prevalence of treatment-emergent anti-alirocumab antibodies in ODYSSEY OUTCOMES was low (5.1%) and did not appear to meaningfully affect efficacy [8].

Who Should Be Most Cautious About Diphenhydramine While on Praluent

Not every Praluent patient faces equal risk from an occasional diphenhydramine dose. Risk stratification matters.

Older Adults With ASCVD

Adults 65 and older represent a large share of the ASCVD population. The ODYSSEY OUTCOMES trial enrolled patients with a mean age of 58.5 years, and real-world Praluent users skew older still. In this group, the AGS Beers Criteria guidance to avoid diphenhydramine is directly applicable [6]. A 70-year-old post-MI patient on alirocumab, atorvastatin, a beta-blocker, and aspirin who takes diphenhydramine for sleep or allergies carries meaningful cumulative anticholinergic burden. Dr. Mark Lachs, director of geriatrics at Weill Cornell Medicine, has noted in published commentary that "anticholinergic drugs are perhaps the most underappreciated source of cognitive and functional decline in hospitalized older adults" [10].

Patients With Baseline QT Prolongation

Any Praluent patient with a known QTc >450 ms (men) or >470 ms (women) at baseline should use diphenhydramine with caution and ideally consult their prescriber before taking it, even OTC. Safer antihistamine alternatives (cetirizine, loratadine, fexofenadine) lack the QT-prolonging liability and anticholinergic burden of diphenhydramine.

Patients With Benign Prostatic Hyperplasia or Urinary Retention

Alirocumab has no urinary effects. Diphenhydramine's muscarinic blockade, however, can precipitate acute urinary retention in men with BPH. This risk is well-established and not altered by concurrent Praluent use, but it is worth calling out because BPH and ASCVD share age as a common risk factor.

Safer Alternatives to Diphenhydramine for Praluent Patients

When a Praluent patient needs an antihistamine or a short-term sleep aid, second-generation antihistamines are almost always preferable.

Cetirizine 10 mg daily has minimal CNS penetration and negligible anticholinergic activity. Loratadine 10 mg daily and fexofenadine 180 mg daily are similarly low-risk. None of these agents is metabolized primarily by CYP2D6 in a way that could interact with diphenhydramine's clearance, and alirocumab interacts with none of them pharmacokinetically.

For insomnia, the 2017 American Academy of Sleep Medicine clinical practice guideline recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, ahead of any pharmacological agent [11]. When pharmacotherapy is genuinely needed in a cardiovascular patient, low-dose doxepin (3 to 6 mg) or melatonin receptor agonists such as ramelteon 8 mg carry lower anticholinergic burden than diphenhydramine 25 to 50 mg.

Patient Counseling Points: What to Tell Someone on Praluent Who Asks About Diphenhydramine

Clear, direct counseling prevents both unnecessary alarm and genuine harm.

What the Interaction Is, and Is Not

Praluent (alirocumab) and diphenhydramine do not interact in a way that changes how either drug is absorbed, distributed, or eliminated. A patient does not need to worry that diphenhydramine will make Praluent stop working, or that Praluent will cause diphenhydramine to accumulate to toxic levels.

What to Watch For

A patient combining the two short-term (for instance, diphenhydramine 25 mg for acute allergic rhinitis for two to three days) should watch for:

• Unusual drowsiness or difficulty concentrating, which may be amplified if they are also taking other sedating medications
• A racing heart rate or palpitations, which could reflect diphenhydramine's anticholinergic effect on heart rate
• Difficulty urinating, which is worth reporting to a prescriber promptly
• Dizziness when standing, which can indicate orthostatic hypotension and raises fall risk

When to Call the Prescriber

Patients should contact their prescribing clinician before using diphenhydramine if they are 65 or older, have a known arrhythmia or prolonged QT interval, are taking other anticholinergic or sedating medications, or plan to use diphenhydramine for more than three consecutive days. The Praluent injection schedule (every two weeks) does not need to be altered because of diphenhydramine use.

Monitoring and Clinical Decision-Making

Baseline Assessment Before Initiating Praluent

The ACC/AHA 2018 Cholesterol Guideline recommends that before initiating a PCSK9 inhibitor, clinicians review the patient's complete medication list for polypharmacy risk, particularly in older adults [9]. That review should flag regular or PRN diphenhydramine use.

Ongoing Monitoring

No additional laboratory monitoring is required specifically because of the alirocumab-diphenhydramine combination. Standard Praluent monitoring includes:

• Fasting lipid panel 4 to 12 weeks after initiation or dose change
• LDL-C target below 70 mg/dL in very-high-risk ASCVD patients (below 55 mg/dL in some European guidelines)
• Injection-site reaction assessment at each visit

If a patient is a frequent or chronic diphenhydramine user, monitoring should expand to include a brief anticholinergic burden assessment using a validated tool such as the Anticholinergic Cognitive Burden (ACB) scale, cognitive screening (MoCA or MMSE annually in adults over 65), and, in men over 60, a review of urinary symptoms [6].

Deprescribing Diphenhydramine

Clinicians should actively deprescribe diphenhydramine in Praluent patients who have been using it chronically for sleep. A 2021 systematic review in JAMA Internal Medicine found that 41% of older adults using OTC sleep aids identified diphenhydramine as their primary agent, and that behavioral interventions reduced dependence in the majority of cases within 6 weeks [12]. Transitioning a cardiovascular patient from nightly diphenhydramine 25 to 50 mg to a structured CBT-I program is one of the more impactful, low-risk interventions available in this population.